BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) have been assigned an average recommendation of “Moderate Buy” from the twenty-five brokerages that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, seven have given a hold recommendation and seventeen have given a buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $90.0417.

BMRN has been the subject of a number of analyst reports. Truist Financial raised their price objective on BioMarin Pharmaceutical from $80.00 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday, December 23rd. Sanford C. Bernstein decreased their target price on shares of BioMarin Pharmaceutical from $95.00 to $88.00 and set an “outperform” rating for the company in a research report on Monday, November 3rd. Royal Bank Of Canada restated a “sector perform” rating and issued a $66.00 price target on shares of BioMarin Pharmaceutical in a research report on Tuesday, October 28th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of BioMarin Pharmaceutical in a research note on Monday, December 29th. Finally, Barclays decreased their price objective on shares of BioMarin Pharmaceutical from $86.00 to $80.00 and set an “overweight” rating for the company in a research report on Tuesday, October 28th.

BioMarin Pharmaceutical Stock Performance

Shares of BioMarin Pharmaceutical stock opened at $56.21 on Friday. The stock has a market cap of $10.80 billion, a price-to-earnings ratio of 21.13, a P/E/G ratio of 0.63 and a beta of 0.27. BioMarin Pharmaceutical has a twelve month low of $50.76 and a twelve month high of $73.51. The company’s fifty day moving average is $56.20 and its 200 day moving average is $56.03. The company has a quick ratio of 3.10, a current ratio of 4.83 and a debt-to-equity ratio of 0.10.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its earnings results on Monday, October 27th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.20). The company had revenue of $776.13 million for the quarter, compared to the consensus estimate of $782.42 million. BioMarin Pharmaceutical had a return on equity of 9.53% and a net margin of 16.82%.The firm’s revenue for the quarter was up 4.1% on a year-over-year basis. During the same period in the prior year, the business earned $0.91 earnings per share. BioMarin Pharmaceutical has set its FY 2025 guidance at 3.500-3.600 EPS. Sell-side analysts forecast that BioMarin Pharmaceutical will post 3.15 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in BMRN. Nisa Investment Advisors LLC boosted its holdings in shares of BioMarin Pharmaceutical by 7.7% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,741 shares of the biotechnology company’s stock valued at $163,000 after acquiring an additional 195 shares during the last quarter. Securian Asset Management Inc. lifted its position in BioMarin Pharmaceutical by 1.4% during the second quarter. Securian Asset Management Inc. now owns 14,604 shares of the biotechnology company’s stock valued at $803,000 after purchasing an additional 197 shares during the period. Sittner & Nelson LLC boosted its holdings in BioMarin Pharmaceutical by 6.9% in the second quarter. Sittner & Nelson LLC now owns 3,100 shares of the biotechnology company’s stock worth $170,000 after purchasing an additional 200 shares during the last quarter. Grandfield & Dodd LLC grew its position in BioMarin Pharmaceutical by 1.2% in the 3rd quarter. Grandfield & Dodd LLC now owns 18,967 shares of the biotechnology company’s stock worth $1,027,000 after purchasing an additional 217 shares during the period. Finally, EverSource Wealth Advisors LLC grew its position in BioMarin Pharmaceutical by 3.4% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 7,151 shares of the biotechnology company’s stock worth $387,000 after purchasing an additional 235 shares during the period. 98.71% of the stock is owned by institutional investors and hedge funds.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.